ERA Congress 2026: key results and trends

The efficacy of rituximab treatment was observed for both MCD (HR=0.23, 95% CI 0.12-0.43; p<0.0001) and FSGS patients (HR=0.23, 95% CI 0.085-0.60; p=0.0027).

At 28 days, 41 (39%) patients in the polymyxin B group and 23 (45%) in the control group had died, yielding a posterior probability of benefit of 95·3% (APACHE-II adjusted odds ratio 0·67 [95% credible interval 0·39–1·08]).

The composite kidney-cardiovascular endpoint occurred in 65 vs 78 participants in the finerenone and placebo arms, respectively (HR 0.81; 95% CI 0.58, 1.13; p=0.214).

At any time up to M24, 118/238 (49.6%) and 65/238 (27.3%) pts on iptacopan and 55/239 (23.0%) and 19/239 (7.9%) on pbo had UPCR from first morning void <0.5 (HR 2.66 [95% CI 1.92, 3.67]) and <0.3 g/g (HR 3.75 [95% CI 2.24, 6.25]), respectively (post hoc).

Fluid retention AEs occurred in 24 (14.2%) vs 20 (11.8%) participants in the atrasentan and placebo groups, respectively, in the main stratum, and 3 (9.4%) vs 2 (6.3%) participants, respectively, in the SGLT2i stratum.

The most common TEAEs (incidence≥5%) were upper respiratory tract infection (13.6% vs. 0% for placebo) and hyperlipidemia (7.6% vs. 4.8%).

Symptomatic hypotension, an AE of special interest, occurred in 10.7% of participants in the pooled nurandociguat arms (2.5 mg: 5.6%;5 mg: 5.6%;10 mg: 10.3%; 15 mg: 11.3%; 20 mg: 20.6%; placebo: 1.6%).

Adverse events occurred in 54.1% and 47.6% of patients in the zilebesiran and placebo groups, respectively.